Navigation Links
Unsuspected protein determines resistance to breast cancer treatment
Date:2/4/2008

An innovative research approach has identified a previously unsuspected protein as a key player in the resistance to particular forms of breast cancer therapy. The study, published by Cell Press in the February issue of Cancer Cell, significantly advances the understanding of the molecular response to breast cancer therapies that target estrogen signaling.

Most breast tumors express estrogen receptor and are dependent on estrogen signaling. Drugs that target this characteristic, such as tamoxifen, have had a major impact on breast cancer therapy as they interfere with the ability of estrogen to activate its receptor and, as a result, limit cellular proliferation.

However, although widely used, the effectiveness of tamoxifen is profoundly limited by the development of drug resistance. All patients with metastatic disease and 40% of early-stage breast cancer patients treated with tamoxifen eventually relapse with tamoxifen-resistant disease, explains lead author Professor Alan Ashworth from the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research in London, England.

To develop a better understanding of the molecular events that contribute to the development of treatment resistance, Prof. Ashworth, Dr. Christopher J. Lord and colleagues used a sophisticated and highly selective loss-of-function RNA interference screening method to identify genes that, when silenced, cause tamoxifen resistance. The researchers identified Cyclin-Dependent Kinase 10 (CDK10) as a critical component of the response to tamoxifen and other therapies that target estrogen signaling.

Examination of signaling molecules downstream of CDK10 led the authors to propose that CDK10 normally represses the ETS2 transcription factor and that the loss of CDK10 expression results in relief of ETS2 repression and upregulation of c-RAF transcription. Enhanced c-RAF activation results in activation of mitogen-activated protein kinase and increased cyclin D1 expression, both previously linked to tamoxifen resistance. Together, these events link tamoxifen with a loss of reliance on estrogen signaling.

Importantly, the researchers also found that in patients treated with tamoxifen, drug resistance occurred significantly earlier in those with tumors that express low levels of CDK10. Furthermore, methylation of the CDK10 gene also correlated with resistance. Methylation of genes is well-established as a means by which gene expression can be controlled and suggests a mechanism that could switch off CDK10 expression in tumor cells.

Drug resistance is a serious problem for women with breast cancer. Its devastating for a patient to see their cancer return because of resistance, especially after enduring a long course of treatment and after a long period of remission. Through this work, weve identified some of the factors that control this effect and in the future we may be able to use this information to decide which treatments to give to patients to avoid resistance, says Prof. Ashworth.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
4. Emory researchers identify signaling protein for multiple myeloma
5. Human C-reactive protein regulates myeloma tumor cell growth and survival
6. Lowering Blood Protein Wont Help Kidney Patients
7. Blood protein detects lung cancer, even at earliest stage
8. Natural Protein Could Help Spot, Treat Liver Cancer
9. Heat shock proteins are co-opted for cancer
10. How adhesive protein causes malaria
11. Loss of gene leads to protein splicing and buildup of toxic proteins in neurons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , ... March 01, 2017 , ... ... healing grace in the lives of those who hear His voice. “Cleansing Thoughts; ... a retired Christian bookstore proprietor who enjoys boating, gardening and crocheting baby items ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... “Our Pure Need of Obedience to the ... preparation for His return. “Our Pure Need of Obedience to the Law of God” is ... to attend missionary school. He and his wife, Anika, and children have since dedicated their ...
(Date:2/28/2017)... ... ... e-Zest Solutions ( http://www.e-zest.com ) – Digital Transformation leader ... intelligent mobile platform that is enabling sales people at small businesses to Fortune ... users in mind unlike most enterprise software, to improve their productivity by making ...
(Date:2/28/2017)... ... February 28, 2017 , ... Many of the country’s top ... Solutions to Healthcare’s Greatest Challenges,” during Intalere’s 2017 Executive Forum, taking place March ... Forum assembles the best and brightest healthcare leaders to exchange experiences, expertise and ...
(Date:2/28/2017)... Baltimore, MD (PRWEB) , ... February 28, 2017 , ... ... Healthcare are co-hosting a Wellness Day on March 4, 2017 from 10:00 a.m. to ... San Mateo and Menaul Blvds. , The goal of the Wellness Day is to ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... , March 1, 2017 The global  Intraoperative Neuromonitoring ... a new report by Grand View Research, Inc. The intraoperative neuromonitoring market is ... to the hospitals adopting intraoperative monitoring in a wide spectrum of surgeries. ... ... Grand View Research Logo ...
(Date:2/28/2017)... -- Prefilled Syringes Market: Scope and Segmentation Download ... report provides a forecast and analysis of the ... levels. It provides historical data of 2015 along ... of revenue (US$ Mn) and volume (Bn Units). ... an outlook on prefilled syringes consumption globally. It ...
(Date:2/28/2017)... , Feb. 28, 2017 Persistence Market ... global dysphagia management market in a new publication ... Forecast 2016-2024." As the name suggests, we have ... geographical regions and on the basis of the ... assessment of the opportunities available to all the ...
Breaking Medicine Technology: